Supplementary data: Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma

These are peer-reviewed supplementary materials for the article 'Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma' published in the Journal of Comparative Effectiveness Research.Supplemental Table 1: Study design and patient eligibility criteria for KarMMa and MAMMOTHSupplemental Table 2: Summary of patient baseline characteristics in CC population from MAMMOTH with the ide-cel population from KarMMa before and after matching to the CC population from MAMMOTHSupplemental Figure 1: HRs of OS for ide-cel versus conventional care based on the triple- or quad-refractory population from MAMMOTHSupplemental Figure 2: HRs of OS for ide-cel versus conventional care based on the penta-refractory population from MAMMOTHAim: To compare the efficacy of idecabtagene vicleucel (ide-cel, bb2121) versus conventional care (CC) in triple-class exposed relapsed and refractory multiple myeloma (RRMM) patients. Patients & methods: A matching-adjusted indirect comparison was conducted using individual patient-level data from the pivotal, phase II, single-arm KarMMa trial (NCT03361748) and aggregate-level data from MAMMOTH, the largest independent observational study of CC in heavily pretreated RRMM patients. Results: Ide-cel improved overall response rate (odds ratio: 5.30; 95% CI: 2.96–9.51), progression-free survival (hazard ratio: 0.50; 95% CI: 0.36–0.70) and overall survival (hazard ratio: 0.37; 95% CI: 0.25–0.56) versus CC. Conclusion: These results suggest ide-cel offers improvements in clinical outcomes relative to CC in this heavily pretreated RRMM population.

本数据集为发表于《比较疗效研究杂志》的论文《idecabtagene vicleucel（ide-cel，bb2121）与常规治疗在多发性骨髓瘤（MM）三线暴露复发难治性患者中的间接治疗比较》的同行评审补充材料。补充表1：KarMMa和MAMMOTH研究的试验设计及患者入选标准；补充表2：MAMMOTH研究中CC人群的基线特征总结，包括与KarMMa研究中ide-cel人群的匹配前后的比较；补充图1：基于MAMMOTH研究中三线或四线耐药人群的ide-cel与常规治疗的总生存期（OS）的HRs；补充图2：基于MAMMOTHA研究中五线耐药人群的ide-cel与常规治疗的总生存期（OS）的HRs。研究目的：比较idecabtagene vicleucel（ide-cel，bb2121）与常规治疗（CC）在多发性骨髓瘤（MM）三线暴露复发难治性患者中的疗效。患者与方法：通过匹配调整的间接比较，利用关键性、II期、单臂KarMMa试验（NCT03361748）的个体患者水平数据和MAMMOTH（在重度预处理复发难治性MM患者中最大的独立观察性研究）的汇总数据。结果：ide-cel相较于CC提高了总缓解率（优势比：5.30；95%CI：2.96–9.51）、无进展生存期（风险比：0.50；95%CI：0.36–0.70）和总生存期（风险比：0.37；95%CI：0.25–0.56）。结论：这些结果表明，ide-cel相对于CC在此重度预处理复发难治性MM人群中提供了临床结局的改善。